The Quantellect read.As of Nov 19, 2026, 8 active firms cover Connect Biopharma Holdings Ltd: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $4.00 to $9.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $5.88 sits 801% above the current $0.65. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.15 next quarter toward $-0.83 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.88
+800.9% upside
Average target across 8 active firms as of Nov 19, 2026 vs $0.65 current
Highest Target$9.00
Average Target$5.88
Lowest Target$4.00
Detailed analyst forecasts for CNTB
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate CNTB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CNTB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.29 – $0.10 · 5 analysts · -44% YoY
Next period, 5 analysts expect Connect Biopharma Holdings Ltd to earn $-0.15 a share (range $-0.29 – $0.10), versus $-0.27 a year earlier. Full-year consensus is $-0.98, growing to $-0.83 the year after.
REVENUE · NEXT QUARTER
$27.0M
Range $0 – $100.7M · 5 analysts
Revenue is expected to reach $27.0M (range $0 – $100.7M). Full-year consensus is $54.7M, rising to $100.0M next year.
Top analysts covering Connect Biopharma Holdings Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CNTB.
#1
Julian Harrison
BTIG · Rank #183
Buy
$5.00+666.8% to target
Overall win rate
41%
+ Follow
#2
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$6.00+820.1% to target
Overall win rate
44%
+ Follow
#3
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$9.00+1280.2% to target
Overall win rate
40%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$7.00+973.5% to target
Overall win rate
38%
+ Follow
#5
Thomas Smith
Leerink Partners · Rank #412
Buy
No targeton CNTB
Overall win rate
41%
+ Follow
CNTB stock forecast FAQ
What is CNTB's average 12-month price target?+
The 8 active firms with a live target average $5.88 for Connect Biopharma Holdings Ltd over the next 12 months, ranging from a $9.00 high to a $4.00 low, as of Nov 19, 2026.
Is CNTB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CNTB?+
The Street-high target is $9.00 (Lake Street), and the Street-low is $4.00 (Leerink Partners). The average of all 8 active-firm targets is $5.88.
How many active Wall Street firms cover CNTB?+
8 active firms have a recognized rating on Connect Biopharma Holdings Ltd as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CNTB?+
Among analysts who currently cover CNTB, Julian Harrison of BTIG has the strongest overall Quantellect track record (Rank #183). Their current call is Buy with a $5.00 target.
What is Connect Biopharma Holdings Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.29 – $0.10) across 5 analysts. Full-year EPS is projected at $-0.98, rising to $-0.83 the following year.
How much revenue is Connect Biopharma Holdings Ltd expected to report next quarter?+
Consensus revenue is $27.0M (range $0 – $100.7M). Full-year revenue is projected at $54.7M, growing to $100.0M next year.
Have analysts been upgrading or downgrading CNTB lately?+
As of Nov 19, 2026, 8 of 8 active firms rate CNTB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CNTB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.